(Q30326186)

18 June 2017

1 reference

title

What has been learned from measuring health-related quality of life in clinical oncology. (English)

1 reference

18 June 2017

1 reference

Osoba D

1

1 reference

18 June 2017

1 October 1999

1 reference

European Journal of Cancer

18 June 2017

1 reference

18 June 2017

35

1 reference

18 June 2017

11

1 reference

18 June 2017

1565-1570

1 reference

The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions

18 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Self-rating symptom checklists: a simple method for recording and evaluating symptom control in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Quality-of-Life Assessment: Patient Compliance With Questionaire Completion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer--a lesson from the real world--the Swiss Group for Clinical Cancer Research SAKK

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Lessons learned from measuring health-related quality of life in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Patients' experiences using a computerized program with a touch-sensitive video monitor for the assessment of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Compliance in quality of life data: a Norwegian experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Ensuring the quality of quality of life data: the Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Part

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study G

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Quality of life during chemotherapy in non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Improved control of emesis and quality of life with ondansetron in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Quality of life consequences of chemotherapy-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Quality of life assessment. An independent prognostic variable for survival in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Measurement of health status. Ascertaining the minimal clinically important difference

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

The use of significant others as proxy raters of the quality of life of patients with brain cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Value of caregiver ratings in evaluating the quality of life of patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Why are missing quality of life data a problem in clinical trials of cancer therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Growth curve model analysis for quality of life data.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Health status assessment for the twenty-first century: item response theory, item banking and computer adaptive testing

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Incomplete quality of life data in randomized trials: missing forms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

Identifying the types of missingness in quality of life data from clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900192-6

7 January 2021

10.1016/S0959-8049(99)00192-6

Identifiers

DOI

1 reference

18 June 2017

1 reference

PubMed ID

10673963